tiprankstipranks
Trending News
More News >
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Advertisement

Cellectar Biosciences (CLRB) Stock Statistics & Valuation Metrics

Compare
1,428 Followers

Total Valuation

Cellectar Biosciences has a market cap or net worth of $15.55M. The enterprise value is $2.75M.
Market Cap$15.55M
Enterprise Value$2.75M

Share Statistics

Cellectar Biosciences has 3,192,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,192,040
Owned by Insiders12.03%
Owned by Institutions1.04%

Financial Efficiency

Cellectar Biosciences’s return on equity (ROE) is -3.12 and return on invested capital (ROIC) is -320.67%.
Return on Equity (ROE)-3.12
Return on Assets (ROA)-1.75
Return on Invested Capital (ROIC)-320.67%
Return on Capital Employed (ROCE)-3.22
Revenue Per Employee0.00
Profits Per Employee-4.05M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Cellectar Biosciences is ―. Cellectar Biosciences’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value0.96
Price to FCF
Price to Operating Cash Flow-0.23
PEG Ratio

Income Statement

In the last 12 months, Cellectar Biosciences had revenue of 0.00 and earned -44.58M in profits. Earnings per share was -40.72.
Revenue0.00
Gross Profit0.00
Operating Income-51.78M
Pretax Income-44.52M
Net Income-44.58M
EBITDA-51.49M
Earnings Per Share (EPS)-40.72

Cash Flow

In the last 12 months, operating cash flow was -34.58M and capital expenditures -61.29K, giving a free cash flow of -34.64M billion.
Operating Cash Flow-34.58M
Free Cash Flow-34.64M
Free Cash Flow per Share-10.85

Dividends & Yields

Cellectar Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.22
52-Week Price Change-92.49%
50-Day Moving Average5.22
200-Day Moving Average11.89
Relative Strength Index (RSI)48.14
Average Volume (3m)151.83K

Important Dates

Cellectar Biosciences upcoming earnings date is Oct 30, 2025, TBA (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date

Financial Position

Cellectar Biosciences as a current ratio of 2.58, with Debt / Equity ratio of 6.07%
Current Ratio2.58
Quick Ratio2.58
Debt to Market Cap0.00
Net Debt to EBITDA0.44
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Cellectar Biosciences has paid 66.00K in taxes.
Income Tax66.00K
Effective Tax Rate>-0.01

Enterprise Valuation

Cellectar Biosciences EV to EBITDA ratio is 0.18, with an EV/FCF ratio of 0.19.
EV to Sales0.00
EV to EBITDA0.18
EV to Free Cash Flow0.19
EV to Operating Cash Flow0.19

Balance Sheet

Cellectar Biosciences has $11.04M in cash and marketable securities with $453.51K in debt, giving a net cash position of -$10.59M billion.
Cash & Marketable Securities$11.04M
Total Debt$453.51K
Net Cash-$10.59M
Net Cash Per Share-$3.32
Tangible Book Value Per Share$9.31

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Cellectar Biosciences is $15.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.20
Price Target Upside215.35% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast73.37%

Scores

Smart Score2
AI Score34
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis